Cloning and Characterization of Four Rabbit Aldo-Keto Reductases Featuring Broad

Total Page:16

File Type:pdf, Size:1020Kb

Cloning and Characterization of Four Rabbit Aldo-Keto Reductases Featuring Broad DMD Fast Forward. Published on February 7, 2014 as DOI: 10.1124/dmd.113.056044 DMD FastThis Forward.article has not Published been copyedited on and February formatted. The7, 2014final version as doi:10.1124/dmd.113.056044 may differ from this version. DMD #56044 Cloning and characterization of four rabbit aldo-keto reductases featuring broad substrate specificity for xenobiotic and endogenous carbonyl compounds: Relationship with multiple forms of drug ketone reductases Satoshi Endo, Toshiyuki Matsunaga, Yuki Arai, Akira Ikari, Kazuo Tajima, Ossama El-Kabbani, Shigeru Yamano, Akira Hara, Yukio Kitade Gifu Pharmaceutical University, Gifu, Japan (S.E., T.M., Y.A., A.I.); Faculty of Downloaded from Pharmaceutical Sciences, Hokuriku University, Kanazawa, Japan (K.T.); Monash Institute of Pharmaceutical Sciences, Monash University, Victoria, Australia (O.E.); Faculty of dmd.aspetjournals.org Pharmaceutical Sciences, Fukuoka University, Fukuoka, Japan (S.Y.); and Faculty of Engineering (A.H., Y.K.), Gifu University, Gifu, Japan at ASPET Journals on October 2, 2021 1 Copyright 2014 by the American Society for Pharmacology and Experimental Therapeutics. DMD Fast Forward. Published on February 7, 2014 as DOI: 10.1124/dmd.113.056044 This article has not been copyedited and formatted. The final version may differ from this version. DMD #56044 Running title: RABBIT DRUG KETONE REDUCTASES Address correspondence to: Dr. Satoshi Endo, Laboratory of Biochemistry, Gifu Pharmaceutical University, Gifu 501-1196, Japan, E-mail: [email protected]. Downloaded from The number of text pages: 39 The number of tables: 7 dmd.aspetjournals.org The number of figures: 4 The number of references: 54 The number of footnote: 1 at ASPET Journals on October 2, 2021 The number of words in the Abstract: 248 The number of words in Introduction: 696 The number of words in Discussion: 1497 ABBREVIATIONS: AKR, aldo-keto reductase; CBR, carbonyl reductase; HSD, hydroxy- steroid dehydrogenase; LR, loxoprofen reductase; MI, 2-(1-hydroxyethyl)-7-(2-hydroxy-3- isopropylaminopropoxy)benzofuran; NR, naloxone reductase; PG, prostaglandin; RT, reverse transcription; SDR, short-chain dehydrogenase/reductase; TBE, 6-tert-butyl-2,3-epoxy-5- cyclohexene-1,4-dione. 2 DMD Fast Forward. Published on February 7, 2014 as DOI: 10.1124/dmd.113.056044 This article has not been copyedited and formatted. The final version may differ from this version. DMD #56044 ABSTRACT: Multiple forms of reductases for several drug ketones were isolated from rabbit liver, but their interrelationship and physiological roles remain unknown. We isolated cDNAs for four aldo-keto reductases (AKRs: 1C30, 1C31, 1C32 and 1C33), which share high amino acid sequence identity with the partial sequences of two rabbit naloxone reductases. The four recombinant enzymes reduced a variety of carbonyl compounds, including endogenous α-dicarbonyls (such as isatin and diacetyl), aldehydes (such as farnesal and 4-oxo-2-nonenal) and ketosteroids. They differed in specificity for drug ketones and ketosteroids. Although Downloaded from daunorubicin and befunolol were common substrates of all the enzymes, other drugs were reduced specifically by the enzymes shown in parentheses: naloxone (AKR1C30, AKR1C32 dmd.aspetjournals.org and AKR1C33); metyrapone (AKR1C32 and AKR1C33); loxoprofen (AKR1C31 and AKR1C32); ketotifen (AKR1C30), and naltrexone and fenofibric acid (AKR1C33). AKR1C30 reduced only 17-keto-5β-androstanes, whereas the other enzymes were active at ASPET Journals on October 2, 2021 towards 3/17/20-ketosteroids, and AKR1C33 further reduced 3-keto groups of bile acids and 7α-hydroxy-5β-cholestanes. In addition, AKR1C30, AKR1C31, AKR1C32 and AKR1C33 were selectively inhibited by carbenoxolone, baccharin, phenolphthalein and zearalenone, respectively. The mRNAs for the four enzymes were ubiquitously expressed in male rabbit tissues, in which highly expressed tissues were the brain, heart, liver, kidney, intestine, colon and testis (for AKR1C30 and AKR1C31), brain, heart, liver, kidney, testis, lung and adrenal gland (for AKR1C32), and liver and intestine (for AKR1C33). The data suggest that the four enzymes correspond to the multiple drug-ketone reductases in rabbits, and function in the metabolisms of steroids, isatin and reactive carbonyl compounds, and bile acid synthesis. 3 DMD Fast Forward. Published on February 7, 2014 as DOI: 10.1124/dmd.113.056044 This article has not been copyedited and formatted. The final version may differ from this version. DMD #56044 Introduction Carbonyl reduction into the alcohol metabolites is an important Phase-I metabolism of carbonyl-containing drugs, which include more than 30 pharmacologically relevant drugs (Hoffmann and Maser, 2007; Barski et al., 2008). Various carbonyl compounds in the environment also enter the body as xenobiotics and environmental pollutants. In addition, many endogenous carbonyl compounds are formed through metabolisms of biogenic amines, steroids, prostaglandins (PGs) and sugars, lipid peroxidation and glycation. To excrete and detoxify the chemically divergent carbonyl compounds, several NADPH-dependent Downloaded from reductases with broad substrate specificity for carbonyl compounds exist in the body. The enzymes with known primary structures are grouped into two distinct protein families: the dmd.aspetjournals.org short-chain dehydrogenase/reductase (SDR) (Hoffmann and Maser, 2007) and aldo-keto reductase (AKR) (Barski et al., 2008; Jin and Penning, 2007) superfamilies. Although fifteen of such carbonyl-reducing enzymes are known in humans (Matsunaga et al., 2006; at ASPET Journals on October 2, 2021 Oppermann, 2007), major enzymes responsible for the reduction of drug ketones are carbonyl reductase (CBR) and 11β-hydroxysteroid dehydrogenase (HSD) type 1 in the SDR superfamily (Hoffmann and Maser, 2007), and those belonging to the AKR superfamily are cytosolic HSD isoforms (AKR1C1, AKR1C2, AKR1C3 and AKR1C4) (Barski et al., 2008; Matsunaga et al., 2006), as well as aldehyde reductase, aldose reductase, aldose reductase-like protein (AKR1B10) and/or aflatoxin reductase that reduce daunorubicin and doxorubicin (Bains et al., 2010). AKR1B10, AKR1C1 and AKR1C3 are suggested to be involved in proliferation of several types of cancer, and their selective inhibitors are expected to be useful for cancer treatments (El-Kabbani et al., 2011; Byrns et al., 2011; Matsunaga et al., 2013). In laboratory animal rats or mice, five AKRs similar to the human HSD isoforms have been suggested to reduce xenobiotic carbonyl compounds (Matsunaga et al., 2006; Ishikura et al., 2006a; 2006b), but their reactivity towards drug ketones has been scarcely studied. In 4 DMD Fast Forward. Published on February 7, 2014 as DOI: 10.1124/dmd.113.056044 This article has not been copyedited and formatted. The final version may differ from this version. DMD #56044 contrast, rabbit reductases for several drug ketones were studied, since they had been reported to be as a class of drug metabolizing enzymes (Bachur, 1976) and extremely active carbonyl-drug reduction potential was found in rabbit liver cytosol (Ahmed et al., 1978;1979). The studies on reductases for daunorubicin, oxisuran, metyrapone and naloxone indicate that each reductase exists in multiple forms in the liver cytosol (Ahmed et al., 1978;1979; Sawada and Hara, 1979; Felsted et al., 1980). Subsequently, two of four multiple forms of rabbit naloxone reductase (NR1 and NR2) were shown to belong to the AKR superfamily by their Downloaded from partial protein sequencing, and differ from each other in their stereospecific reduction of the drug and substrate specificity for naltrexone and 3/17-hydroxysteroids (Yamano et al., 1999). A major form of four loxoprofen reductases (LRs) in rabbit liver cytosol also shows 3- and dmd.aspetjournals.org 17-ketosteroid reductase activity (Tanaka et al., 1989). The presence of multiple forms of befunolol reductase in rabbit liver cytosol was also reported, although one form was identified as CBR (Imamura et al., 1989). However, in addition to the properties of the other multiple at ASPET Journals on October 2, 2021 forms, the entire primary sequences of the enzymes other than CBR (Gonzalez et al., 1995) have not been studied, and the interrelationship among the enzymes remains unknown. Recently, recombinant rabbit 20α-HSD (AKR1C5) and 3-hydroxyhexobarbital dehydrogenase (AKR1C29) have been reported to exhibit NADPH-linked reductase activity towards several drug ketones. AKR1C5 reduces xenobiotic carbonyl compounds including befunolol and ketotifen, although it is expressed specifically in rabbit ovary and uterus (Endo et al., 2013a). AKR1C29 ubiquitously expressed in rabbit tissues reduces befunolol, daunorubicin, naloxone and loxoprofen, as well as endogenous substrates such as 3-, 17- and 20-ketosteroids and PGD2 (Endo et al., 2013c). However, the properties and/or amino acid sequences of AKR1C5 and AKR1C29 are different from those of NR1 and NR2, and the major form of LR. Current rabbit genomic analysis has predicted four genes encoding the AKR1C subfamily proteins that share high sequence identity with the partial sequences of 5 DMD Fast Forward. Published on February 7, 2014 as DOI: 10.1124/dmd.113.056044 This article has not been copyedited and formatted. The final version may differ from this version. DMD #56044 NR1 and NR2. In this study, we cloned the cDNAs for the four proteins that have been assigned as AKR1C30, AKR1C31, AKR1C32 and AKR1C33 in the AKR superfamily (http://www.med.upenn.edu/akr/).
Recommended publications
  • Farnesyl Phosphatase, a Corpora Allata
    Florida International University FIU Digital Commons Department of Biological Sciences College of Arts, Sciences & Education 8-5-2013 Farnesyl Phosphatase, a Corpora allata Enzyme Involved in Juvenile Hormone Biosynthesis in Aedes aegypti Pratik Nyati Department of Biological Sciences, Florida International University, [email protected] Marcela Nouzova Department of Biological Sciences, Florida International University, [email protected] Crisalejandra Rivera-Perez Department of Biological Sciences, Florida International University,, [email protected] Mark E. Clifton Department of Biological Sciences, Florida International University Jamie G. Mayoral Department of Biological Sciences, Florida International University See next page for additional authors Follow this and additional works at: https://digitalcommons.fiu.edu/cas_bio Part of the Biology Commons Recommended Citation Nyati P, Nouzova M, Rivera-Perez C, Clifton ME, Mayoral JG, et al. (2013) Farnesyl Phosphatase, a Corpora allata Enzyme Involved in Juvenile Hormone Biosynthesis in Aedes aegypti. PLoS ONE 8(8): e71967. doi:10.1371/journal.pone.0071967 This work is brought to you for free and open access by the College of Arts, Sciences & Education at FIU Digital Commons. It has been accepted for inclusion in Department of Biological Sciences by an authorized administrator of FIU Digital Commons. For more information, please contact [email protected]. Authors Pratik Nyati, Marcela Nouzova, Crisalejandra Rivera-Perez, Mark E. Clifton, Jamie G. Mayoral, and Fernando G. Noriega This article is available at FIU Digital Commons: https://digitalcommons.fiu.edu/cas_bio/131 Farnesyl Phosphatase, a Corpora allata Enzyme Involved in Juvenile Hormone Biosynthesis in Aedes aegypti Pratik Nyati, Marcela Nouzova, Crisalejandra Rivera-Perez, Mark E. Clifton, Jaime G. Mayoral, Fernando G.
    [Show full text]
  • The Role of Bile Acids in Overcoming Resistance to Chemotherapy By
    The Role of Bile Acids in Overcoming Resistance to Chemotherapy by Simon Chewchuk A thesis submitted as a partial fulfillment of the Requirements for the degree of Doctor of Philosophy (Ph.D.) in Biomolecular Sciences The Faculty of Graduate Studies Laurentian University Sudbury, Ontario, Canada © Simon Chewchuk, 2017 ii Abstract: In the context of cancer therapy, resistance to chemotherapy agents is a serious threat to patient welfare. In these circumstances, patients can either present with cancers that are naturally resistant to conventional therapy, referred to as innate resistance, or with cancers that become resistant following treatment, referred to as acquired resistance. In this thesis, we address the phenomenon of acquired drug resistance, involving cell lines selected for resistance to the anthracycline, doxorubicin. In the first study, we examined the role of the aldo-keto reductases AKR1C3 and AKR1B10 in doxorubicin resistance, enzymes that can hydroxylate doxorubicin to a less toxic form (doxorubicinol). Additionally, these enzymes can function to promote estrogen biosynthesis from estrone, which can have significant effects on cell growth and survival. We demonstrated in the first study that AKR1C3 and AKR1B10 are expressed at higher levels in doxorubicin resistant MCF-7 cells than their isogenic control counterparts. This change in expression correlated very well with increased estrogen synthesis. siRNA-mediated reduction in AKR1C3 and/or AKR1B10 transcript expression had no major effect on doxorubicin resistance, suggesting that these enzymes are not sufficient to mediate the doxorubicin resistance phenotype and that other mechanisms of doxorubicin resistance exist in these cells. We did, however, note that a pharmacological inhibitor of AKR enzymes (a bile acid termed β-cholanic acid) was effective in reversing doxorubicin resistance in doxorubicin-selected cell lines.
    [Show full text]
  • (10) Patent No.: US 8119385 B2
    US008119385B2 (12) United States Patent (10) Patent No.: US 8,119,385 B2 Mathur et al. (45) Date of Patent: Feb. 21, 2012 (54) NUCLEICACIDS AND PROTEINS AND (52) U.S. Cl. ........................................ 435/212:530/350 METHODS FOR MAKING AND USING THEMI (58) Field of Classification Search ........................ None (75) Inventors: Eric J. Mathur, San Diego, CA (US); See application file for complete search history. Cathy Chang, San Diego, CA (US) (56) References Cited (73) Assignee: BP Corporation North America Inc., Houston, TX (US) OTHER PUBLICATIONS c Mount, Bioinformatics, Cold Spring Harbor Press, Cold Spring Har (*) Notice: Subject to any disclaimer, the term of this bor New York, 2001, pp. 382-393.* patent is extended or adjusted under 35 Spencer et al., “Whole-Genome Sequence Variation among Multiple U.S.C. 154(b) by 689 days. Isolates of Pseudomonas aeruginosa” J. Bacteriol. (2003) 185: 1316 1325. (21) Appl. No.: 11/817,403 Database Sequence GenBank Accession No. BZ569932 Dec. 17. 1-1. 2002. (22) PCT Fled: Mar. 3, 2006 Omiecinski et al., “Epoxide Hydrolase-Polymorphism and role in (86). PCT No.: PCT/US2OO6/OOT642 toxicology” Toxicol. Lett. (2000) 1.12: 365-370. S371 (c)(1), * cited by examiner (2), (4) Date: May 7, 2008 Primary Examiner — James Martinell (87) PCT Pub. No.: WO2006/096527 (74) Attorney, Agent, or Firm — Kalim S. Fuzail PCT Pub. Date: Sep. 14, 2006 (57) ABSTRACT (65) Prior Publication Data The invention provides polypeptides, including enzymes, structural proteins and binding proteins, polynucleotides US 201O/OO11456A1 Jan. 14, 2010 encoding these polypeptides, and methods of making and using these polynucleotides and polypeptides.
    [Show full text]
  • Characterization of Juvenile Hormone Biosynthetic Enzymes in the Mosquito, Aedes Aegypti Pratik Nyati Florida International University, [email protected]
    Florida International University FIU Digital Commons FIU Electronic Theses and Dissertations University Graduate School 11-5-2014 Characterization of Juvenile Hormone Biosynthetic Enzymes in the Mosquito, Aedes aegypti Pratik Nyati Florida International University, [email protected] Follow this and additional works at: http://digitalcommons.fiu.edu/etd Part of the Biochemistry, Biophysics, and Structural Biology Commons, Biology Commons, and the Entomology Commons Recommended Citation Nyati, Pratik, "Characterization of Juvenile Hormone Biosynthetic Enzymes in the Mosquito, Aedes aegypti" (2014). FIU Electronic Theses and Dissertations. Paper 1688. http://digitalcommons.fiu.edu/etd/1688 This work is brought to you for free and open access by the University Graduate School at FIU Digital Commons. It has been accepted for inclusion in FIU Electronic Theses and Dissertations by an authorized administrator of FIU Digital Commons. For more information, please contact [email protected]. FLORIDA INTERNATIONAL UNIVERSITY Miami, Florida CHARACTERIZATION OF JUVENILE HORMONE BIOSYNTHETIC ENZYMES IN THE MOSQUITO, AEDES AEGYPTI A dissertation submitted in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY in BIOLOGY by Pratik Nyati 2014 To: Interim Dean Michael R. Heithaus College of Arts and Sciences This dissertation, written by Pratik Nyati, and entitled Characterization of Juvenile Hormone Biosynthetic Enzymes in the Mosquito, Aedes aegypti, having been approved in respect to style and intellectual content, is referred to you for judgment. We have read this dissertation and recommend that it be approved. ______________________________________ Alejandro Barbieri ______________________________________ Lidia Kos ______________________________________ Lou W. Kim ______________________________________ Kalai Mathee ______________________________________ Fernando G. Noriega, Major Professor Date of Defense: November 5, 2014 This dissertation of Pratik Nyati is approved.
    [Show full text]
  • 9, 10-Phenanthrenequinone Induces Monocytic Differentiation of U937
    1598 Note Biol. Pharm. Bull. 35(9) 1598–1602 (2012) Vol. 35, No. 9 9,10-Phenanthrenequinone Induces Monocytic Differentiation of U937 Cells through Regulating Expression of Aldo-Keto Reductase 1C3 Toshiyuki Matsunaga,*,a Mika Hosogai,a Marina Arakaki,a Satoshi Endo,a Ossama El-Kabbani,b and Akira Haraa a Laboratory of Biochemistry, Gifu Pharmaceutical University; Gifu 501–1196, Japan: and b Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences; Victoria 3052, Australia. Received March 9, 2012; accepted June 5, 2012 Persistent inhalation of diesel exhaust particles results in damaged lung cells through formation of re- active oxygen species (ROS), but the details of the toxicity mechanism against monocytes are poorly under- stood. In this study, we used human promyelomonocytic U937 cells as surrogates of monocytes and investi- gated the toxicity mechanism initiated by exposure to 9,10-phenanthrenequinone (9,10-PQ), a major quinone component in diesel exhaust particles. A 24-h incubation with 9,10-PQ provoked apoptotic cell death, which was due to signaling through the enhanced ROS generation and concomitant caspase activation. Flow cy- tometric analyses of U937 cells after long-term exposure to 9,10-PQ revealed induction of differentiation that was evidenced by increasing expression of CD11b/CD18, a cell-surface marker for monocytic differentiation into macrophages. The 9,10-PQ-induced differentiation was significantly abolished by ROS inhibitors, sug- gesting that ROS generation contributes to cell differentiation. The 9,10-PQ treatment increased the expres- sion of aldo-keto reductase (AKR) 1C3, which reached a peak at 1 to 2 d post-treatment and then declined.
    [Show full text]
  • Ep 2679685 A1
    (19) TZZ _T (11) EP 2 679 685 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 01.01.2014 Bulletin 2014/01 C12N 15/52 (2006.01) C12P 7/18 (2006.01) C12N 1/00 (2006.01) (21) Application number: 13001196.8 (22) Date of filing: 06.08.2008 (84) Designated Contracting States: • Van Dien, Stephen J. AT BE BG CH CY CZ DE DK EE ES FI FR GB GR San Diego, CA 92121 (US) HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT •Burk,Mark J. RO SE SI SK TR San Diego, CA 92121 (US) (30) Priority: 10.08.2007 US 891602 (74) Representative: HOFFMANN EITLE Patent- und Rechtsanwälte (62) Document number(s) of the earlier application(s) in Arabellastrasse 4 accordance with Art. 76 EPC: 81925 München (DE) 08782639.2 / 2 185 708 Remarks: (71) Applicant: Genomatica, Inc. •This application was filed on 11-03-2013 as a San Diego, CA 92121 (US) divisional application to the application mentioned under INID code 62. (72) Inventors: •Claims filed after the date of filing of the application/ • Burgard, Anthony P. after the date of receipt of the divisional application San Diego, CA 92121 (US) (Rule 68(4) EPC). (54) Methods and organisms for the growth- coupled production of 1,4-butanediol (57) The invention provides a non- naturally occurring microorganismcomprising one ormore gene disruptions, the one or more gene disruptions occurring in genes en- coding an enzyme obligatory to coupling 1,4-butanediol production to growth of the microorganism when the gene disruption reduces an activity of the enzyme, whereby theone or more gene disruptions confers stable growth- coupled production of 1,4- butanediol onto the non-natu- rally occurring microorganism.
    [Show full text]
  • Investigating Labdane-Related Diterpenoids Biosynthetic Network In
    Iowa State University Capstones, Theses and Graduate Theses and Dissertations Dissertations 2012 Investigating labdane-related diterpenoids biosynthetic network in rice: characterization of cytochromes P450 and short-chain alcohol dehydrogenases/reductase Yisheng Wu Iowa State University Follow this and additional works at: https://lib.dr.iastate.edu/etd Part of the Biochemistry Commons Recommended Citation Wu, Yisheng, "Investigating labdane-related diterpenoids biosynthetic network in rice: characterization of cytochromes P450 and short-chain alcohol dehydrogenases/reductase" (2012). Graduate Theses and Dissertations. 12680. https://lib.dr.iastate.edu/etd/12680 This Dissertation is brought to you for free and open access by the Iowa State University Capstones, Theses and Dissertations at Iowa State University Digital Repository. It has been accepted for inclusion in Graduate Theses and Dissertations by an authorized administrator of Iowa State University Digital Repository. For more information, please contact [email protected]. Investigating labdane-related diterpenoids biosynthetic network in rice: Characterization of cytochromes P450 and short-chain alcohol dehydrogenases/reductase by Yisheng Wu A dissertation submitted to the graduate faculty in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY Major: Biochemistry Program of Study Committee: Reuben Peters, Major Professor Gustavo MacIntosh Thomas Bobik Bing Yang Mark Hargrove Iowa State University Ames, Iowa 2012 Copyright © Yisheng Wu , 2012. All
    [Show full text]
  • Table S1 All 373 Compounds in the Two Herbs and the Corresponding
    Electronic Supplementary Material (ESI) for Integrative Biology This journal is © The Royal Society of Chemistry 2012 Table S1 All 373 compounds in the two herbs and the corresponding predicted OB Molecule Name OB (%) LM294* forsythidmethylester 100 LM387* 7'-epi-8-hydroxypinoresinol 94.8 LM394* 1,7-dihydroxyxanthone 93.8 LM289* (+)-pinoresinol monomethyl ether 92.9 LM285* egenine 90.3 LM298* matairesinol 89.6 JM77* loniceracetalide A 89.4 JM63* alpha-cedrol 89.3 JM1* (-)-(3r,8s,9r,9as,10as)-9-ethenyl-8-(beta-d-glucopyranosyloxy)-2,3,9,9a,10,10a-hexahy 87.5 dro-5-oxo-5h,8h-pyrano[4,3-d]oxazolo[3,2-a]pyridine-3-carboxylic acid JM200 (z)-3-methyl-2-(2-pentenyl)-2-cyclopenten-1-one 87.1 LM304* phillyrin 85.1 JM57* 7-epi-loganin 85.1 JM173*/LM camphol 83.3 398* LM287* epipinoresinol 82.8 JM27 2-methyl-1-butanol 81.2 LM356* (+)-lariciresinol 80.0 JM170* ledol 79.7 LM430 safynol 78.3 JM16 1-pentanol 76.2 LM414* campherenol 76.0 LM386* 8-hydroxypinoresinol 75.9 LM428* onjixanthone i 75.9 LM345* (+)-phillygenin 74.4 LM305* (+)-pinoresinol 74.1 JM113* sweroside 73.6 JM107* secologanic acid 73.3 JM13 1-hexen-3-one 72.3 LM309* 3-ethyl-7hydroxyphthalide 70.5 JM250* shuangkangsu 70.1 LM274* astragalin 68.6 LM331 4-hydroxyphenylacetic acid 68.3 LM299* (3r,4s,5r)-5-(3,4-dimethoxyphenyl)-3,4-bis(hydroxymethyl)dihydrofuran-2(3h)-one 67.5 JM225*/ camphor 67.4 LM399* LM338* (-)-7’-o-methylegenine 67.1 JM189 trimethyl isothiazole 66.6 JM29 cis-2-penten-1-ol 66.4 JM199 cis-linalool oxide 66.2 LM288 erythritol 65.8 Electronic Supplementary Material (ESI) for
    [Show full text]
  • Functional and Structural Studies of AKR1B15 and AKR1B16: Two Novel Additions to Human and Mouse Aldo-Keto Reductase Superfamily
    ADVERTIMENT. Lʼaccés als continguts dʼaquesta tesi queda condicionat a lʼacceptació de les condicions dʼús establertes per la següent llicència Creative Commons: http://cat.creativecommons.org/?page_id=184 ADVERTENCIA. El acceso a los contenidos de esta tesis queda condicionado a la aceptación de las condiciones de uso establecidas por la siguiente licencia Creative Commons: http://es.creativecommons.org/blog/licencias/ WARNING. The access to the contents of this doctoral thesis it is limited to the acceptance of the use conditions set by the following Creative Commons license: https://creativecommons.org/licenses/?lang=en Functional and structural studies of AKR1B15 and AKR1B16: Two novel additions to human and mouse aldo-keto reductase superfamily Mem`oriapresentada per JOAN GIMENEZ´ DEJOZ per optar al Grau de Doctor en Bioqu´ımicai Biologia Molecular Treball realitzat al departament de Bioqu´ımicai Biologia Molecular de la Universitat Aut`onomade Barcelona, sota la direcci´odels Doctors SERGIO PORTE´ ORDUNA, JAUME FARRES´ VICEN´ i XAVIER PARES´ CASASAMPERA Sergio Port´eOrduna Jaume Farr´esVic´en Xavier Par´esCasasampera Joan Gim´enezDejoz Bellaterra, 17 de juny de 2016 2 Agra¨ıments En primer lloc vull agrair als caps del grup, el Dr. Jaume Farr´esi el Dr. Xavier Par´esl'oportunitat de posar un peu a la ci`encia,iniciar-me en la carrera cient´ıfica,els seus bons consells i l’obtenci´o final d'aquesta tesi. Tamb´evoldria agrair especialment a tots els ADHs amb qui he compartit laboratori, sense vosaltres aix`ono hauria estat possible. Gr`aciesper aguantar tants dies a les fosques! Al Sergio-せんせい, per tot el que m'has ensenyat durant aquests anys, la bona guia, direcci´o, les inacabables correccions, per ensenyar-me a ser cr´ıticamb la meva pr`opiafeina i intentar sempre ser rigor´osi auto exigent tant amb els experiments com amb la redacci´oi preparaci´ode les figures (repassar cada figura mil cops buscant defectes abans de donar-la per bona ja s'ha convertit en costum) i tots i cada un dels inacabables \Podries..."que tant hem trobat a faltar en la `epoca final.
    [Show full text]
  • The Role of AKR1B10 in Physiology and Pathophysiology
    H OH metabolites OH Review The Role of AKR1B10 in Physiology and Pathophysiology Satoshi Endo 1,* , Toshiyuki Matsunaga 2 and Toru Nishinaka 3 1 Laboratory of Biochemistry, Gifu Pharmaceutical University, Gifu 501-1196, Japan 2 Education Center of Green Pharmaceutical Sciences, Gifu Pharmaceutical University, Gifu 502-8585, Japan; [email protected] 3 Laboratory of Biochemistry, Faculty of Pharmacy, Osaka Ohtani University, Tondabayashi 584-8540, Osaka, Japan; [email protected] * Correspondence: [email protected] Abstract: AKR1B10 is a human nicotinamide adenine dinucleotide phosphate (NADPH)-dependent reductase belonging to the aldo-keto reductase (AKR) 1B subfamily. It catalyzes the reduction of aldehydes, some ketones and quinones, and interacts with acetyl-CoA carboxylase and heat shock protein 90α. The enzyme is highly expressed in epithelial cells of the stomach and intestine, but down-regulated in gastrointestinal cancers and inflammatory bowel diseases. In contrast, AKR1B10 expression is low in other tissues, where the enzyme is upregulated in cancers, as well as in non- alcoholic fatty liver disease and several skin diseases. In addition, the enzyme’s expression is elevated in cancer cells resistant to clinical anti-cancer drugs. Thus, growing evidence supports AKR1B10 as a potential target for diagnosing and treating these diseases. Herein, we reviewed the literature on the roles of AKR1B10 in a healthy gastrointestinal tract, the development and progression of cancers and acquired chemoresistance, in addition to its gene regulation, functions, and inhibitors. Keywords: aldo-keto reductases; AKR1B10; biomarkers Citation: Endo, S.; Matsunaga, T.; Nishinaka, T. The Role of AKR1B10 in 1. Introduction Physiology and Pathophysiology.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2012/0266329 A1 Mathur Et Al
    US 2012026.6329A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2012/0266329 A1 Mathur et al. (43) Pub. Date: Oct. 18, 2012 (54) NUCLEICACIDS AND PROTEINS AND CI2N 9/10 (2006.01) METHODS FOR MAKING AND USING THEMI CI2N 9/24 (2006.01) CI2N 9/02 (2006.01) (75) Inventors: Eric J. Mathur, Carlsbad, CA CI2N 9/06 (2006.01) (US); Cathy Chang, San Marcos, CI2P 2L/02 (2006.01) CA (US) CI2O I/04 (2006.01) CI2N 9/96 (2006.01) (73) Assignee: BP Corporation North America CI2N 5/82 (2006.01) Inc., Houston, TX (US) CI2N 15/53 (2006.01) CI2N IS/54 (2006.01) CI2N 15/57 2006.O1 (22) Filed: Feb. 20, 2012 CI2N IS/60 308: Related U.S. Application Data EN f :08: (62) Division of application No. 1 1/817,403, filed on May AOIH 5/00 (2006.01) 7, 2008, now Pat. No. 8,119,385, filed as application AOIH 5/10 (2006.01) No. PCT/US2006/007642 on Mar. 3, 2006. C07K I4/00 (2006.01) CI2N IS/II (2006.01) (60) Provisional application No. 60/658,984, filed on Mar. AOIH I/06 (2006.01) 4, 2005. CI2N 15/63 (2006.01) Publication Classification (52) U.S. Cl. ................... 800/293; 435/320.1; 435/252.3: 435/325; 435/254.11: 435/254.2:435/348; (51) Int. Cl. 435/419; 435/195; 435/196; 435/198: 435/233; CI2N 15/52 (2006.01) 435/201:435/232; 435/208; 435/227; 435/193; CI2N 15/85 (2006.01) 435/200; 435/189: 435/191: 435/69.1; 435/34; CI2N 5/86 (2006.01) 435/188:536/23.2; 435/468; 800/298; 800/320; CI2N 15/867 (2006.01) 800/317.2: 800/317.4: 800/320.3: 800/306; CI2N 5/864 (2006.01) 800/312 800/320.2: 800/317.3; 800/322; CI2N 5/8 (2006.01) 800/320.1; 530/350, 536/23.1: 800/278; 800/294 CI2N I/2 (2006.01) CI2N 5/10 (2006.01) (57) ABSTRACT CI2N L/15 (2006.01) CI2N I/19 (2006.01) The invention provides polypeptides, including enzymes, CI2N 9/14 (2006.01) structural proteins and binding proteins, polynucleotides CI2N 9/16 (2006.01) encoding these polypeptides, and methods of making and CI2N 9/20 (2006.01) using these polynucleotides and polypeptides.
    [Show full text]
  • All Enzymes in BRENDA™ the Comprehensive Enzyme Information System
    All enzymes in BRENDA™ The Comprehensive Enzyme Information System http://www.brenda-enzymes.org/index.php4?page=information/all_enzymes.php4 1.1.1.1 alcohol dehydrogenase 1.1.1.B1 D-arabitol-phosphate dehydrogenase 1.1.1.2 alcohol dehydrogenase (NADP+) 1.1.1.B3 (S)-specific secondary alcohol dehydrogenase 1.1.1.3 homoserine dehydrogenase 1.1.1.B4 (R)-specific secondary alcohol dehydrogenase 1.1.1.4 (R,R)-butanediol dehydrogenase 1.1.1.5 acetoin dehydrogenase 1.1.1.B5 NADP-retinol dehydrogenase 1.1.1.6 glycerol dehydrogenase 1.1.1.7 propanediol-phosphate dehydrogenase 1.1.1.8 glycerol-3-phosphate dehydrogenase (NAD+) 1.1.1.9 D-xylulose reductase 1.1.1.10 L-xylulose reductase 1.1.1.11 D-arabinitol 4-dehydrogenase 1.1.1.12 L-arabinitol 4-dehydrogenase 1.1.1.13 L-arabinitol 2-dehydrogenase 1.1.1.14 L-iditol 2-dehydrogenase 1.1.1.15 D-iditol 2-dehydrogenase 1.1.1.16 galactitol 2-dehydrogenase 1.1.1.17 mannitol-1-phosphate 5-dehydrogenase 1.1.1.18 inositol 2-dehydrogenase 1.1.1.19 glucuronate reductase 1.1.1.20 glucuronolactone reductase 1.1.1.21 aldehyde reductase 1.1.1.22 UDP-glucose 6-dehydrogenase 1.1.1.23 histidinol dehydrogenase 1.1.1.24 quinate dehydrogenase 1.1.1.25 shikimate dehydrogenase 1.1.1.26 glyoxylate reductase 1.1.1.27 L-lactate dehydrogenase 1.1.1.28 D-lactate dehydrogenase 1.1.1.29 glycerate dehydrogenase 1.1.1.30 3-hydroxybutyrate dehydrogenase 1.1.1.31 3-hydroxyisobutyrate dehydrogenase 1.1.1.32 mevaldate reductase 1.1.1.33 mevaldate reductase (NADPH) 1.1.1.34 hydroxymethylglutaryl-CoA reductase (NADPH) 1.1.1.35 3-hydroxyacyl-CoA
    [Show full text]